These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Should off-label drug use be off-the-table? Rivkees SA J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432 [No Abstract] [Full Text] [Related]
4. "Creating hope" and other incentives for drug development for children. Connor E; Cure P Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312 [TBL] [Abstract][Full Text] [Related]
5. Developing treatments for inborn errors: incentives available to the clinician. Haffner ME Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976 [TBL] [Abstract][Full Text] [Related]
6. Orphan drugs and orphan tests in the USA. Thoene JG Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190 [No Abstract] [Full Text] [Related]
7. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
8. Adopting orphan drugs--two dozen years of treating rare diseases. Haffner ME N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556 [No Abstract] [Full Text] [Related]
9. The Minor Use and Minor Species Animal Health Act: past, present, and future. Haley CJ Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456 [No Abstract] [Full Text] [Related]
10. The routes to orphan drug designation--our recent experience at the FDA. Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120 [No Abstract] [Full Text] [Related]
11. Orphan drug regulations. Final rule. Food and Drug Administration, HHS Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079 [TBL] [Abstract][Full Text] [Related]
13. Rare opportunities appear on the horizon to treat rare diseases. Torres C Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483 [No Abstract] [Full Text] [Related]
14. Ethical considerations in orphan drug approval and use. Kesselheim AS Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660 [TBL] [Abstract][Full Text] [Related]
15. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Wellman-Labadie O; Zhou Y Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435 [TBL] [Abstract][Full Text] [Related]
16. The Orphan Drug Act Revisited. Thomas S; Caplan A JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155 [No Abstract] [Full Text] [Related]
17. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry. Karst KR Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732 [No Abstract] [Full Text] [Related]
18. Regulators adopt more orphan drugs. Reardon S Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293 [No Abstract] [Full Text] [Related]
19. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis. Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464 [TBL] [Abstract][Full Text] [Related]
20. First treatment for Hunter syndrome. FDA Consum; 2006; 40(6):5. PubMed ID: 17333554 [No Abstract] [Full Text] [Related] [Next] [New Search]